NCT06620835 2025-07-29
OPTALK
Groupe Francais De Pneumo-Cancerologie
Phase 2 Recruiting
Clinical Trials
3 trialsNCT03654105 2024-03-07
SMILE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Active not recruiting
NCT02839681 2019-05-21
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated